⚕️ BMO Hosts First Obesity Summit on Future of Obesity Care Market
Tuesday, 19 March 2024 02:35.PM
- Healthcare industry experts and leaders will convene at inaugural BMO Obesity Summit to examine outlook and trends in obesity treatment -
BMO will host its first Obesity Summit on March 20, 2024 in New York City. The conference will target buy-side investors who want to hear from leading biotech and pharmaceutical companies developing medical weight-management therapeutics and stakeholders across the continuum of care and delivery. Topics straight from the headlines will be discussed via panels and presentations, including:
• A panel on the emerging therapeutic landscape
• The Patient's Voice: a conversation with patients on GLP-1+ therapy
• Obesity 101 with Intellihealth, featuring Dr Katherine Saunders
• Care delivery featuring Beth Israel Lahey Health, Weight Watchers, and Intellihealth
• A key opinion leader's insights on metabolic research, featuring Weill Cornell Medical • College's Dr Louis J. Aronne
• A payors panel addressing coverage and access, featuring Prime Therapeutics
"Important conversations need to happen around the development and delivery of obesity care," said Evan Seigerman, Senior Biotechnology & Pharmaceuticals Analyst, BMO. "This summit is about having those discussions and sharing ideas and solutions from thought leaders and experts who can move the dial to meet challenges to deliver care for patients with obesity and metabolic disease."
BMO analysts, including Evan Seigerman, will host discussions with leading life sciences companies, including:
• Altimmune
• Amgen
• Capital Rx
• Corbus Pharmaceuticals
• Eli Lilly & Co.
• Novo Nordisk
• Intellihealth
• Prime Therapeutics
• Scholar Rock
• Structure Therapeutics
• Terns Pharmaceuticals
• Weight Watchers
SOURCE: BMO Financial Group
*** This article is not an advertisement and for information only.
- Related materials: